Revolutionizing CAR T Therapy: Insights from New Zealand’s Breakthrough Webinar
Discover how cutting-edge automation and clinical innovation are transforming CAR T cell therapy straight from the experts leading the charge in New Zealand.
What You’ll Learn
The Cocoon Platform Advantage
Learn how Lanza’s Cocoon platform is streamlining cell therapy manufacturing with automation, reducing costs, shortening production timelines, and enabling decentralized treatment centers.
Bio Ora’s Vision for the Southern Hemisphere
Hear from Dr. Lawrence Cooper and the Bio Ora team on their mission to commercialize CD19 CAR T therapy in New Zealand—making it the first of its kind in the region.
Clinical Success Stories
Explore compelling Phase 1 trial results showing a 53% complete response rate with minimal toxicity—benchmarking favorably against global leaders like Yescarta.
Next Steps in Global Expansion
Get a preview of Bio Ora’s Phase 2 trial, its plans for commercial manufacturing in Christchurch, and its strategy for medical tourism and market entry into Australia
Why It Matters
This webinar is a must-watch for biotech professionals, clinicians, and investors interested in:
- Scalable, cost-effective CAR T manufacturing
- Regulatory innovation in New Zealand
- Real-world patient outcomes and safety data
- The future of cell therapy in underserved regions